Barclays’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-4,700
| Closed | -$1.73M | – | 5338 |
|
|
2024
Q4 | $1.73M | Hold |
4,700
| – | – | ﹤0.01% | 2994 |
|
|
2024
Q3 | $2.44M | Buy |
+4,700
| New | +$2.51M | ﹤0.01% | 2693 |
|
|
2024
Q2 | – | Sell |
-4,700
| Closed | -$2.44M | – | 4992 |
|
|
2024
Q1 | $2.44M | Hold |
4,700
| – | – | ﹤0.01% | 2406 |
|
|
2023
Q4 | $2.22M | Sell |
4,700
-4,700
| -50% | -$2.17M | ﹤0.01% | 2832 |
|
|
2023
Q3 | $4.09M | Buy |
+9,400
| New | +$4.26M | ﹤0.01% | 1448 |
|
|
2023
Q1 | – | Sell |
-6,000
| Closed | -$3.08M | – | 5160 |
|
|
2022
Q4 | $3.08M | Buy |
+6,000
| New | +$3.05M | ﹤0.01% | 1964 |
|
|
2022
Q1 | – | Sell |
-40,200
| Closed | -$18.6M | – | 5119 |
|
|
2021
Q4 | $18.6M | Buy |
40,200
+16,200
| +68% | +$6.82M | 0.01% | 976 |
|
|
2021
Q3 | $8.95M | Buy |
+24,000
| New | +$9.12M | ﹤0.01% | 1257 |
|
|
2021
Q1 | – | Sell |
-23,500
| Closed | -$7.55M | – | 4820 |
|
|
2020
Q4 | $7.55M | Buy |
23,500
+20,000
| +571% | +$6.14M | ﹤0.01% | 1295 |
|
|
2020
Q3 | $940K | Hold |
3,500
| – | – | ﹤0.01% | 2746 |
|
|
2020
Q2 | $920K | Sell |
3,500
-20,000
| -85% | -$5.34M | ﹤0.01% | 2837 |
|
|
2020
Q1 | $5.33M | Sell |
23,500
-45,000
| -66% | -$12.3M | ﹤0.01% | 1409 |
|
|
2019
Q4 | $20.7M | Sell |
68,500
-5,600
| -8% | -$1.54M | 0.01% | 938 |
|
|
2019
Q3 | $17.8M | Sell |
74,100
-8,600
| -10% | -$2.36M | 0.01% | 945 |
|
|
2019
Q2 | $23.3M | Buy |
82,700
+52,800
| +177% | +$14.4M | 0.01% | 832 |
|
|
2019
Q1 | $8.58M | Buy |
29,900
+7,600
| +34% | +$2.2M | 0.01% | 1318 |
|
|
2018
Q4 | $5.86M | Sell |
22,300
-46,000
| -67% | -$12.6M | ﹤0.01% | 1496 |
|
|
2018
Q3 | $18.7M | Buy |
68,300
+9,900
| +17% | +$2.57M | 0.01% | 888 |
|
|
2018
Q2 | $13.9M | Buy |
58,400
+45,900
| +367% | +$10.6M | 0.01% | 1012 |
|
|
2018
Q1 | $2.75M | Sell |
12,500
-8,900
| -42% | -$2.09M | ﹤0.01% | 2152 |
|
|
2017
Q4 | $4.82M | Sell |
21,400
-23,200
| -52% | -$4.94M | ﹤0.01% | 1679 |
|
|
2017
Q3 | $8.47M | Buy |
44,600
+25,600
| +135% | +$4.87M | 0.01% | 1156 |
|
|
2017
Q2 | $3.58M | Sell |
19,000
-1,600
| -8% | -$287K | ﹤0.01% | 1734 |
|
|
2017
Q1 | $3.41M | Sell |
20,600
-38,700
| -65% | -$6.16M | ﹤0.01% | 1614 |
|
|
2016
Q4 | $8.53M | Buy |
59,300
+34,400
| +138% | +$4.61M | 0.01% | 1031 |
|
|
2016
Q3 | $3.12M | Buy |
24,900
+9,600
| +63% | +$1.24M | ﹤0.01% | 1639 |
|
|
2016
Q2 | $2.01M | Sell |
15,300
-1,900
| -11% | -$260K | ﹤0.01% | 2002 |
|
|
2016
Q1 | $2.37M | Sell |
17,200
-2,100
| -11% | -$281K | ﹤0.01% | 1766 |
|
|
2015
Q4 | $2.68M | Sell |
19,300
-2,800
| -13% | -$386K | ﹤0.01% | 1789 |
|
|
2015
Q3 | $3.09M | Sell |
22,100
-32,000
| -59% | -$4.81M | ﹤0.01% | 1745 |
|
|
2015
Q2 | $8.87M | Buy |
54,100
+22,000
| +69% | +$3.52M | 0.01% | 1114 |
|
|
2015
Q1 | $4.94M | Sell |
32,100
-237,600
| -88% | -$33.8M | 0.01% | 1569 |
|
|
2014
Q4 | $33.7M | Sell |
269,700
-17,400
| -6% | -$2.15M | 0.03% | 510 |
|
|
2014
Q3 | $34.2M | Sell |
287,100
-4,500
| -2% | -$516K | 0.03% | 472 |
|
|
2014
Q2 | $31.2M | Buy |
291,600
+218,500
| +299% | +$22.5M | 0.03% | 478 |
|
|
2014
Q1 | $7.24M | Sell |
73,100
-33,100
| -31% | -$2.99M | 0.01% | 1408 |
|
|
2013
Q4 | $9.77M | Sell |
106,200
-114,400
| -52% | -$10.2M | 0.01% | 1271 |
|
|
2013
Q3 | $18.3M | Buy |
220,600
+131,600
| +148% | +$11.3M | 0.02% | 721 |
|
|
2013
Q2 | $7.28M | Buy |
+89,000
| New | +$6.66M | 0.01% | 1323 |
|
Other funds holding ELV
VCM
VPM
Barclays's ELV Position: Q1 2026 in Review
Barclays increased its Elevance Health (ELV) stake by 121% in Q1 2026, buying an estimated $151M and bringing the position to 838,900 shares worth $246M. The position accounts for 0.06% of the portfolio, ranked #243.
Barclays first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $582M in Q4 2023. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- Barclays held 838,900 shares of Elevance Health worth $246M as of Q1 2026.
- Barclays bought 460,014 Elevance Health shares in Q1 2026, an estimated $151M.
- Elevance Health made up 0.06% of Barclays's portfolio in Q1 2026, its #243 holding.
- Barclays first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
- Barclays's Elevance Health position peaked at $582M in Q4 2023.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.